Comparative movements of four large fish species in a lowland river.

A multi-year radio-telemetry data set was used to comparatively examine the concurrent movements of the adults of three large-bodied Australian native freshwater fishes (Murray cod Maccullochella peelii, trout cod Maccullochella macquariensis and golden perch Macquaria ambigua) and the introduced carp Cyprinus carpio. The study was conducted over a reach scale in the regulated Murray River in south-eastern Australia. Differences were identified in the movements among these species. The predominant behaviour was the use of small movements (<1 km) for all species, and although larger-scale movements (>1 km) did occur, the frequency varied considerably among species. Large-scale movements were least evident for M. macquariensis and more common for M. ambigua and C. carpio with these two species also having a greater propensity to change locations. Macquaria ambigua displayed the largest movements and more M. ambigua moved on a 'continual' basis. Although a degree of site fidelity was evident for all species, the highest levels were exhibited by M. macquariensis and M. peelii. Homing was also evident to some degree in all species, but was greatest for M. peelii.

Age estimation and validation for South Pacific albacore Thunnus alalunga.

Validated estimates of age are presented for albacore Thunnus alalunga, sampled from a large part of the south-western Pacific Ocean, based on counts of annual opaque growth zones from transverse sections of otoliths. Counts of daily increments were used to estimate the location of the first opaque growth zone, which was completed before the first assumed birthday. The periodicity of opaque zones was estimated by marginal increment analysis and an oxytetracycline mark-recapture experiment. Both validation methods indicated that opaque zones formed over the austral summer and were completed by autumn to winter (April to August). The direct comparison of age estimates obtained from otoliths and dorsal-fin spines of the same fish indicated bias, which was assumed to be due to poor increment clarity and resorption of early growth zones in spines, resulting in imprecise age estimates. As such, age estimates from otoliths are considered to be more accurate than those from spines for T. alalunga. This is consistent with results for a growing number of tropical and temperate tuna Thunnini species. It is recommend that validated counts of annual growth zones from sectioned otoliths is used as the preferred method for estimating age-based parameters for assessment and management advice for these important stocks.

Clinical evaluation of methoximorpholino-doxorubicin (FCE 23762) in dogs with spontaneous malignancies.

We conducted a clinical evaluation of FCE 23762, a methoxymorpholino analog of doxorubicin, in 48 dogs with metastatic, nonresectable, or chemotherapy-resistant spontaneous malignancies at an initial dosage of 50-60 microg/kg IV every 3 weeks. Clinical evidence of toxicity was minimal; 6 dogs developed grades I, II, and III hematologic toxicities after the 1st treatment, and 1 dog developed grade II gastrointestinal toxicity. One dog became pancytopenic 4 months after discontinuation of FCE 23762. No other adverse effects were noted. Partial or complete remissions were observed in 32% of the dogs. Responses were observed both in previously untreated dogs and in those that had received prior chemotherapy, including doxorubicin. FCE 23762 is a promising new antineoplastic agent that can be used safely in dogs with cancer; doses higher than those used in this study may be used eventually in practice.

Assessment of mammary lactogenic receptor changes in pregnant rabbits.

Lactogenic receptor was purified from rabbit mammary tissue and used to generate an antiserum in goats. The purified lactogenic receptor material bound lactogenic hormones specifically and reversibly. Antiserum generated in a goat bound a labeled human growth hormone/receptor complex; this was displaced by nonlabeled solubilized receptor preparations. This was used as a radioimmunoassay and was able to detect 0.037 fmol of lactogenic receptor. The specificity of the radioimmunoassay for lactogenic receptor was supported by three lines of evidence; first, the ligand used in the radioimmunoassay was an iodine 125-labeled human growth hormone/receptor combination; therefore, only membrane protein with structural homology to the protein which bound 125I-labeled human growth hormone competed for binding to the antiserum; second, depletion of radioreceptor binding sites by affinity chromatography with ovine prolactin as the fixed ligand was detected; third, an increase in breast lactogenic receptor during pregnancy was detected by both radioreceptor assay and the radioimmunoassay. We found a progressive increase in lactogenic receptors by radioimmunoassay which corresponded to parallel increases by radioreceptor assay in rabbit mammary tissue during pregnancy.

Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.

BACKGROUND: 3'-Deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) is a highly lipophilic doxorubicin derivative which possesses potent in vitro and in vivo antitumor activity. Previous phase I studies had been conducted using a single bolus every 28 days. PATIENTS AND METHODS: We conducted a phase I study of FCE 23762 on a daily x3 every 28 days schedule. Thirty patients received 68 cycles of therapy at 5 dose levels (200-600 micrograms/m2/d). RESULTS: Prolonged neutropenia and thrombocytopenia were the dose-limiting toxicities. Other nonhematological toxicities included nausea and vomiting, anorexia, fatigue and transient elevations of serum creatinine and hepatic transaminases. No cardiac toxicity was demonstrated. There were no partial or complete antitumor responses. CONCLUSION: The recommended phase II dose using the schedule defined in this study is 500 micrograms/m2/dx3.

Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors.

PURPOSE: Paclitaxel and gemcitabine possess broad spectra of clinical activity, distinct mechanisms of cytotoxicity, and are differentially affected by mutations in cell-cycle regulatory proteins, such as bcl-2. This phase I trial was designed to identify the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of paclitaxel and gemcitabine when both drugs were given together on a once-every-two-week schedule in patients with solid tumors. PATIENTS AND METHODS: A total of 37 patients were treated at nine different dose levels ranging from paclitaxel 75-175 mg/m2 administered over three hours followed by gemcitabinc 1500-3500 mg/m2 administered over 30-60 minutes. Both drugs were administered on day 1 of a 14-day cycle. Dose escalation was performed in a stepwise manner in which the dose of one drug was escalated while the dose of the other drug was kept constant. RESULTS: Dose limiting toxicity (DLT) was observed at dose level 9: paclitaxel 175 mg/m2 and gemcitabine 3500 mg/m2 in the form of grade 4 neutropenia lasting for > or = 5 days (one patient) and grade 3 elevation of alanine aminotransferase (AST/SGPT) (one patient). An analysis of delivered dose intensity (DI) over the first three cycles revealed that higher dosages of both drugs were delivered at dose level 7, paclitaxel 150 mg/m2 and gemcitabine 3000 mg/m2 dose level, than at the MTD, dose level 8, paclitaxel 150 mg/m2 and gemcitabine 3500 mg/m2. Partial responses were confirmed in two patients with transitional cell carcinoma (one of the bladder, one of the renal pelvis) and in one patient with adenocarcinoma of unknown primary. CONCLUSIONS: Paclitaxel and gemcitabine is a promising drug combination that can be administered safely and repetitively on an every-other-week schedule. Using this drug administration schedule, the recommended phase II dose is paclitaxel 150 mg/m2 and gemcitabine 3000 mg/m2.